Skip to content

An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes

An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes in Healthy Male Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02137590
Acronym
11SEHS
Enrollment
20
Registered
2014-05-14
Start date
2011-09-30
Completion date
2011-11-30
Last updated
2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Spanish Black Radish, Phase I detoxification enzymes, Phase II detoxification enzymes, Acetaminophen

Brief summary

This study will investigate the effect of Spanish Black Radish on phase I and phase II enzyme activity in healthy adult males. The primary objective is to determine the effect on phase I and phase II enzyme activity by measuring plasma and urine acetaminophen metabolite concentrations prior to and after a 28 day supplementation period with Spanish black radish product.

Interventions

DIETARY_SUPPLEMENTSpanish Black Radish product

Sponsors

Standard Process Inc.
CollaboratorINDUSTRY
KGK Science Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
25 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Male age 25 - 35 years * BMI 18 - 25 kg/m2 * Healthy as determined by laboratory results, medical history * Agrees to avoid the consumption of cruciferous vegetables for 14 days prior to baseline and during the study treatment period * Has given voluntary, written, informed consent to participate in the study

Exclusion criteria

* Chronic diseases or any medical conditions * Gall bladder disorders and /or bowel obstruction * Use of prescribed or over the counter medications for the treatment of any acute or chronic conditions * Use of muscle building steroids or body building aids * Use of products containing ingredients derived from the Cruciferae (Brassicaracea) plant family within 14 days prior to randomization * Use of natural health products other than vitamins or minerals within 14 days prior to randomization * Any clinically significant abnormal laboratory value. Meaning a disease process, an exacerbation or worsening of an existing condition, requires further or more frequent monitoring or requires further action(s) to be taken. Clinical significance can only be determined by the Qualified Investigator. * Participation in a clinical research trial within 30 days prior to randomization * Allergy or sensitivity to test product ingredients, Cruciferae/Brassicaracea plant family (includes mustard, cabbage, radish), acetaminophen or foods and beverages provided during the study * Individuals who are cognitively impaired and/or who are unable to give informed consent * Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject * Cannot take acetaminophen within 48 hrs of the baseline appointment or final 4-wk appointment.

Design outcomes

Primary

MeasureTime frameDescription
Effect on Phase I and II enzymes4 weeksThe effect on phase I and phase II enzyme activity determined by measuring plasma and urine acetaminophen metabolite concentrations Subjects will ingest 1000 mg of acetaminophen. Blood will be collected at 0, 2, 4, 6 and 8 hours after acetaminophen dosage for the analysis of plasma acetaminophen metabolites. These measurements will be performed prior to and after 4 weeks of treatment with Spanish Black Radish product.

Secondary

MeasureTime frameDescription
Assessment of Hormone Levels4 weeksAssessment of serum total testosterone, free testosterone and estradiol 17 beta

Other

MeasureTime frameDescription
Blood Safety Parameters4 weeksAssessment of CBC, electrolytes (Na, K, Cl), creatinine, AST, ALT, GGT, and bilirubin
Vital Signs4 weeksAssessment of Blood Pressure and Heart Rate
Adverse Events4 weeksAssessment of any adverse events occurring during the study

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026